Single-Centre Prospective Study of Indigenously Developed Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) (Desidustat) for Treatment of Renal Anemia

作者
Krishnaswamy Sampathkumar,Krishna Priya,Biju Dennis
出处
期刊:Journal of The American Society of Nephrology [American Society of Nephrology]
卷期号:35 (10S)
标识
DOI:10.1681/asn.2024eb8acsqa
摘要

Background: Anemia in dialysis patients impairs quality of life and leads to adverse cardiovascular outcomes. Standard treatments for CKD-associated anemia include EPO analogues and iron supplementation. Desidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), was recently approved in India for treating anemia in CKD patients. This study aims to evaluate the efficacy and safety of Desidustat in patients with dialysis-dependent CKD anemia. Methods: This single-center, prospective study enrolled 68 dialysis-dependent CKD patients with anemia. Patients received Desidustat (Oxemia®) either twice or thrice weekly, depending on their hemoglobin (Hb) levels, and were monitored monthly. Supplemental treatments included iron, vitamin B12, and folic acid as needed. The primary endpoint was the efficacy of Desidustat in increasing Hb levels, while the secondary endpoint assessed its safety profile. Results: The study cohort consisted of 68 patients, 47 (69.11%) male, with a mean age of 56 ± 11.5 years. The majority, 66 (97%), were on maintenance hemodialysis (MHD) twice weekly, while 2 (3%) were on thrice weekly schedules. Desidustat was administered to 35 (51.4%) patients thrice weekly and to 31 (45.6%) patients twice weekly. Among the participants, 40 (58.8%) were EPO-naïve, and 28 (42.8%) had switched from EPO therapy. Significant improvements in Hb levels were observed following Desidustat treatment (p<0.05). Pre-treatment Hb was 7.78 gm/dl, increasing to 8.27 gm/dl after 1 month, 8.71 gm/dl after 2 months, 9.22 gm/dl after 3 months, and 9.94 gm/dl after more than 3 months, with a mean treatment duration of 11.8 ± 6.7 months. Both EPO-naïve patients and those who switched from EPO showed comparable increases in Hb levels. Background therapy included oral iron for 12 (17.6%) patients, intravenous (IV) iron for 52 (76.4%) patients, and vitamin B12 supplementation. Adverse events included mild hyperkalemia in 6 patients and vomiting in 2 patients, both managed appropriately. Conclusion: This study demonstrates that Desidustat is an effective and safe alternative for treating anemia in dialysis-dependent CKD patients. Given its oral administration Desidustat offers a convenient alternative to injectable EPO therapies Funding: Commercial Support - Zydus Pharmaceutical, India

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
充电宝的应助被kay采纳,获得30
刚刚
FashionBoy的应助被典雅的寄真采纳,获得10
1秒前
挽留完成签到,获得积分10
1秒前
2秒前
勤恳易真发布了新的文献求助10
2秒前
我是老大的应助被沫栀采纳,获得10
2秒前
Juvenilesy的应助被jing采纳,获得10
2秒前
3秒前
3秒前
黄豆酱子完成签到,获得积分20
3秒前
星辰大海的应助被wang采纳,获得10
3秒前
3秒前
4秒前
2021发布了新的文献求助10
4秒前
喜悦的厉发布了新的文献求助10
5秒前
科研通AI6.2的应助被123采纳,获得10
5秒前
李健的应助被咕嘟采纳,获得10
6秒前
jyh发布了新的文献求助10
6秒前
7秒前
欣喜咖啡发布了新的文献求助10
8秒前
8秒前
coolru的应助被紫熊采纳,获得10
8秒前
明亮的柚子完成签到,获得积分10
8秒前
aaa完成签到,获得积分20
8秒前
宋琪琪给宋琪琪的求助进行了留言
9秒前
9秒前
ruixinwang发布了新的文献求助10
9秒前
连欢完成签到 ,获得积分10
10秒前
10秒前
CC完成签到 ,获得积分10
10秒前
dra7vu完成签到,获得积分10
10秒前
李林泽完成签到,获得积分10
10秒前
妮妮完成签到 ,获得积分10
10秒前
图图糊涂涂完成签到,获得积分10
11秒前
JamesPei的应助被Sept采纳,获得10
11秒前
LEI完成签到 ,获得积分10
12秒前
椰子水水发布了新的文献求助10
12秒前
liujianxin发布了新的文献求助30
12秒前
美羊羊完成签到,获得积分10
12秒前
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175707
求助须知:如何正确求助?哪些是违规求助? 9567353
关于积分的说明 21792214
捐赠科研通 7770334
什么是DOI,文献DOI怎么找? 3431908
关于科研通互助平台的介绍 2556260
邀请新用户注册赠送积分活动 2477417